Targeting adenosine receptors in the development of cardiovascular therapeutics.
about
Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates.The effect of eplerenone on adenosine formation in humans in vivo: a double-blinded randomised controlled study.Ticagrelor Does Not Inhibit Adenosine Transport at Relevant Concentrations: A Randomized Cross-Over Study in Healthy Subjects In Vivo.Differentiation of mesenchymal stem cells to osteoblasts and chondrocytes: a focus on adenosine receptors.Unveiling the binding mode of adenosine deaminase inhibitors to the active site of the enzyme: implication for rational drug design : presented by Maria P. Abbracchio.CD39-adenosinergic axis in renal pathophysiology and therapeutics.
P2860
Targeting adenosine receptors in the development of cardiovascular therapeutics.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting adenosine receptors in the development of cardiovascular therapeutics.
@en
Targeting adenosine receptors in the development of cardiovascular therapeutics.
@nl
type
label
Targeting adenosine receptors in the development of cardiovascular therapeutics.
@en
Targeting adenosine receptors in the development of cardiovascular therapeutics.
@nl
prefLabel
Targeting adenosine receptors in the development of cardiovascular therapeutics.
@en
Targeting adenosine receptors in the development of cardiovascular therapeutics.
@nl
P2860
P356
P1476
Targeting adenosine receptors in the development of cardiovascular therapeutics.
@en
P2093
Gerard A Rongen
Niels P Riksen
P2860
P304
P356
10.1586/ECP.12.8
P407
P577
2012-03-01T00:00:00Z